Pyxis Oncology reports FY2023 net loss of $73.8M, advances PYX-201 and PYX-106 trials

Pyxis Oncology, Inc.

Net loss of $73.8M ($1.85/share) vs $120.7M ($3.65/share) in FY2022; R&D expenses fell to $49.6M from $86.1M.
Cash, equivalents, and short-term investments $120.8M as of Dec 31, 2023; post-period raised $50M PIPE and $10.8M ATM, extending runway into 2H 2026.
PYX-201 Phase 1: 37 patients dosed; cleared DLT for Cohort 6; escalating to Cohort 7 at 8 mg/kg; initial data expected fall 2024.
PYX-106 Phase 1: 21 patients dosed; Cohort 5 fully enrolled at 8 mg/kg Q2W; preliminary data expected 2H 2024.
Feb 2024 PIPE investors include Deep Track Capital, Ridgeback, Blue Owl, Laurion Capital, StemPoint Capital.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Pyxis Oncology, Inc. reported the full year ended December 31, 2023 results: net income $73.8 million, or ($1.85) per common share.

Period: the full year ended December 31, 2023
Net income: $73.8 million, or ($1.85) per common share
Result: reported results

Exact text from the filing

Net loss was $73.8 million, or ($1.85) per common share, for the year ended December 31, 2023, compared to $120.7 million, or ($3.65) per common share, for the year ended December 31, 2022.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Pyxis Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-034427

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.